Your browser doesn't support javascript.
loading
Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers.
Park, Daniel J; Tao, Kayoko; Le Calvez-Kelm, Florence; Nguyen-Dumont, Tu; Robinot, Nivonirina; Hammet, Fleur; Odefrey, Fabrice; Tsimiklis, Helen; Teo, Zhi L; Thingholm, Louise B; Young, Erin L; Voegele, Catherine; Lonie, Andrew; Pope, Bernard J; Roane, Terrell C; Bell, Russell; Hu, Hao; Huff, Chad D; Ellis, Jonathan; Li, Jun; Makunin, Igor V; John, Esther M; Andrulis, Irene L; Terry, Mary B; Daly, Mary; Buys, Saundra S; Snyder, Carrie; Lynch, Henry T; Devilee, Peter; Giles, Graham G; Hopper, John L; Feng, Bing-Jian; Lesueur, Fabienne; Tavtigian, Sean V; Southey, Melissa C; Goldgar, David E.
Afiliación
  • Park DJ; Genetic Epidemiology Laboratory, Department of Pathology;
  • Tao K; Oncological Sciences and.
  • Le Calvez-Kelm F; Genetic Cancer Susceptibility Group, International Agency for Research on Cancer, Lyon;
  • Nguyen-Dumont T; Genetic Epidemiology Laboratory, Department of Pathology;
  • Robinot N; Genetic Cancer Susceptibility Group, International Agency for Research on Cancer, Lyon;
  • Hammet F; Genetic Epidemiology Laboratory, Department of Pathology;
  • Odefrey F; Genetic Epidemiology Laboratory, Department of Pathology;
  • Tsimiklis H; Genetic Epidemiology Laboratory, Department of Pathology;
  • Teo ZL; Genetic Epidemiology Laboratory, Department of Pathology;
  • Thingholm LB; Genetic Epidemiology Laboratory, Department of Pathology;
  • Young EL; Oncological Sciences and.
  • Voegele C; Genetic Cancer Susceptibility Group, International Agency for Research on Cancer, Lyon;
  • Lonie A; Victorian Life Sciences Computation Initiative;
  • Pope BJ; Department of Computing and Information Systems; Victorian Life Sciences Computation Initiative;
  • Roane TC; University of Texas at Austin, Austin;
  • Bell R; Oncological Sciences and.
  • Hu H; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas;
  • Shankaracharya; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas;
  • Huff CD; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas;
  • Ellis J; The QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia; Departments of.
  • Li J; The QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia; Departments of.
  • Makunin IV; The QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia; Departments of.
  • John EM; Cancer Prevention Institute of California, Fremont; Department of Health Research and Policy, Stanford Cancer Institute, Stanford, California;
  • Andrulis IL; Department of Molecular Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada;
  • Terry MB; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York;
  • Daly M; Fox Chase Cancer Center, Philadelphia, Pennsylvania;
  • Buys SS; Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah;
  • Snyder C; Department of Preventive Medicine, Creighton University, Omaha, Nebraska;
  • Lynch HT; Department of Preventive Medicine, Creighton University, Omaha, Nebraska;
  • Devilee P; Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands; and.
  • Giles GG; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne; Centre for Cancer Epidemiology, The Cancer Council Victoria, Carlton, Victoria;
  • Hopper JL; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne; School of Public Health, Seoul National University, Seoul, Korea.
  • Feng BJ; Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine; Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah;
  • Lesueur F; Genetic Cancer Susceptibility Group, International Agency for Research on Cancer, Lyon; Genetic Epidemiology of Cancer Team, Institut National de la Santé et de la Recherche Medicale (INSERM), U900, Institut Curie, Mines ParisTech, Paris, France;
  • Tavtigian SV; Oncological Sciences and.
  • Southey MC; Genetic Epidemiology Laboratory, Department of Pathology; msouthey@unimelb.edu.au david.goldgar@hsc.utah.edu.
  • Goldgar DE; Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine; Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah; msouthey@unimelb.edu.au david.goldgar@hsc.utah.edu.
Cancer Discov ; 4(7): 804-15, 2014 Jul.
Article en En | MEDLINE | ID: mdl-25050558
ABSTRACT
UNLABELLED Approximately half of the familial aggregation of breast cancer remains unexplained. A multiple-case breast cancer family exome-sequencing study identified three likely pathogenic mutations in RINT1 (NM_021930.4) not present in public sequencing databases RINT1 c.343C>T (p.Q115X), c.1132_1134del (p.M378del), and c.1207G>T (p.D403Y). On the basis of this finding, a population-based case-control mutation-screening study was conducted that identified 29 carriers of rare (minor allele frequency < 0.5%), likely pathogenic variants 23 in 1,313 early-onset breast cancer cases and six in 1,123 frequency-matched controls [OR, 3.24; 95% confidence interval (CI), 1.29-8.17; P = 0.013]. RINT1 mutation screening of probands from 798 multiple-case breast cancer families identified four additional carriers of rare genetic variants. Analysis of the incidence of first primary cancers in families of women carrying RINT1 mutations estimated that carriers were at increased risk of Lynch syndrome-spectrum cancers [standardized incidence ratio (SIR), 3.35; 95% CI, 1.7-6.0; P = 0.005], particularly for relatives diagnosed with cancer under the age of 60 years (SIR, 10.9; 95% CI, 4.7-21; P = 0.0003).

SIGNIFICANCE:

The work described in this study adds RINT1 to the growing list of genes in which rare sequence variants are associated with intermediate levels of breast cancer risk. Given that RINT1 is also associated with a spectrum of cancers with mismatch repair defects, these findings have clinical applications and raise interesting biological questions.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neoplasias Colorrectales Hereditarias sin Poliposis / Proteínas de Ciclo Celular Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Cancer Discov Año: 2014 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neoplasias Colorrectales Hereditarias sin Poliposis / Proteínas de Ciclo Celular Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Cancer Discov Año: 2014 Tipo del documento: Article